{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T22:24:12Z","timestamp":1788387852488,"version":"build-2803163510"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T00:00:00Z","timestamp":1713139200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T00:00:00Z","timestamp":1713139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82370171"],"award-info":[{"award-number":["No. 82370171"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82370171"],"award-info":[{"award-number":["No. 82370171"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82370171"],"award-info":[{"award-number":["No. 82370171"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82370171"],"award-info":[{"award-number":["No. 82370171"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82370171"],"award-info":[{"award-number":["No. 82370171"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82370171"],"award-info":[{"award-number":["No. 82370171"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004829","name":"Science and Technology Department of Sichuan Province","doi-asserted-by":"publisher","award":["No. 2022YFS0191"],"award-info":[{"award-number":["No. 2022YFS0191"]}],"id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004829","name":"Science and Technology Department of Sichuan Province","doi-asserted-by":"publisher","award":["No. 2022YFS0191"],"award-info":[{"award-number":["No. 2022YFS0191"]}],"id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004829","name":"Science and Technology Department of Sichuan Province","doi-asserted-by":"publisher","award":["No. 2022YFS0191"],"award-info":[{"award-number":["No. 2022YFS0191"]}],"id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004829","name":"Science and Technology Department of Sichuan Province","doi-asserted-by":"publisher","award":["No. 2022YFS0191"],"award-info":[{"award-number":["No. 2022YFS0191"]}],"id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004829","name":"Science and Technology Department of Sichuan Province","doi-asserted-by":"publisher","award":["No. 2022YFS0191"],"award-info":[{"award-number":["No. 2022YFS0191"]}],"id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004829","name":"Science and Technology Department of Sichuan Province","doi-asserted-by":"publisher","award":["No. 2022YFS0191"],"award-info":[{"award-number":["No. 2022YFS0191"]}],"id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Minimal residual disease (MRD) is a validated prognostic factor in several hematological malignancies. However, its role in systemic light chain (AL) amyloidosis remains controversial, and this systematic review and meta-analysis aims to fill this gap.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We searched for relevant studies on Pubmed, Embase, and Cochrane Controlled Register of Trials, nine studies involving 451 patients were included and meta-analyzed. This systematic review has been registered in PROSPERO (CRD42023494169).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Our study found that in the group of patients who achieved very good partial response (VGPR) or better, MRD negativity was correlated with higher cardiac and renal response rates [pooled risk ratio (RR)\u2009=\u20090.74 (95% CI 0.62\u20130.89), 0.74 (95% CI 0.64\u20130.87), respectively]. Patients with MRD positivity had a higher hematologic progression rate within two years after MRD detection [pooled RR\u2009=\u200910.31 (95% CI 2.02\u201352.68)]; and a higher risk of hematologic\u2009+\u2009organ progression in the first year [pooled RR\u2009=\u200912.57 (95% CI 1.73\u201391.04)]. Moreover, MRD negativity was correlated\u00a0with a better progression-free survival (PFS) [pooled hazard ratio (HR)\u2009=\u20090.27 (95% CI 0.17\u20130.45)]; but it did not significantly improve the overall survival (OS) [pooled HR\u2009=\u20090.34 (95% CI 0.11\u20131.07)].<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In AL amyloidosis, our study supports that MRD negativity correlates with higher cardiac or renal response rates and indicates a better PFS in the follow-up. However, the correlation between OS and the status of MRD is not significant.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00432-024-05733-2","type":"journal-article","created":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T09:01:59Z","timestamp":1713171719000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Minimal residual disease in systemic light chain amyloidosis: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"150","author":[{"given":"Xuefeng","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengran","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8708-9711","authenticated-orcid":false,"given":"Yu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,15]]},"reference":[{"key":"5733_CR1","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/s11899-021-00633-5","volume":"16","author":"L Bertamini","year":"2021","unstructured":"Bertamini L, D\u2019Agostino M, Gay F (2021) MRD assessment in multiple myeloma: progress and challenges. Curr Hematol Malig Rep 16:162\u2013171. https:\/\/doi.org\/10.1007\/s11899-021-00633-5","journal-title":"Curr Hematol Malig Rep"},{"key":"5733_CR2","doi-asserted-by":"publisher","first-page":"E244","DOI":"10.1002\/ajh.26562","volume":"97","author":"R Chakraborty","year":"2022","unstructured":"Chakraborty R, Hopson M, Bhutani D et al (2022) Impact of bone marrow minimal residual disease status on quality of organ response in systemic AL amyloidosis. Am J Hematol 97:E244\u2013E246. https:\/\/doi.org\/10.1002\/ajh.26562","journal-title":"Am J Hematol"},{"key":"5733_CR3","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.clml.2019.11.005","volume":"20","author":"C Diaz-Pallares","year":"2020","unstructured":"Diaz-Pallares C, Lee H, Luider J et al (2020) Cyclophosphamide, bortezomib and dexamethasone (CyBorD) for the treatment of newly diagnosed AL amyloidosis: impact of response on survival outcomes. Clin Lymphoma Myeloma Leuk 20:394\u2013399. https:\/\/doi.org\/10.1016\/j.clml.2019.11.005","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"5733_CR4","doi-asserted-by":"publisher","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","volume":"22","author":"A Dispenzieri","year":"2004","unstructured":"Dispenzieri A, Gertz MA, Kyle RA et al (2004) Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 22:3751\u20133757. https:\/\/doi.org\/10.1200\/JCO.2004.03.029","journal-title":"J Clin Oncol"},{"key":"5733_CR5","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41408-020-0291-8","volume":"10","author":"A Dispenzieri","year":"2020","unstructured":"Dispenzieri A, Arendt B, Dasari S et al (2020) Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis. Blood Cancer J 10:20. https:\/\/doi.org\/10.1038\/s41408-020-0291-8","journal-title":"Blood Cancer J"},{"key":"5733_CR6","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1002\/ajh.26569","volume":"97","author":"MA Gertz","year":"2022","unstructured":"Gertz MA (2022) Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment. Am J Hematol 97:818\u2013829. https:\/\/doi.org\/10.1002\/ajh.26569","journal-title":"Am J Hematol"},{"key":"5733_CR7","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1001\/jama.2020.5493","volume":"324","author":"MA Gertz","year":"2020","unstructured":"Gertz MA, Dispenzieri A (2020) Systemic amyloidosis recognition, prognosis, and therapy: a systematic review. JAMA 324:79\u201389. https:\/\/doi.org\/10.1001\/jama.2020.5493","journal-title":"JAMA"},{"key":"5733_CR8","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/ajh.20381","volume":"79","author":"MA Gertz","year":"2005","unstructured":"Gertz MA, Comenzo R, Falk RH et al (2005) Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18\u201322 April 2004. Am J Hematol 79:319\u2013328. https:\/\/doi.org\/10.1002\/ajh.20381","journal-title":"Am J Hematol"},{"key":"5733_CR9","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1741-7015-12-2","volume":"12","author":"X Huang","year":"2014","unstructured":"Huang X, Wang Q, Chen W et al (2014) Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial. BMC Med 12:2. https:\/\/doi.org\/10.1186\/1741-7015-12-2","journal-title":"BMC Med"},{"key":"5733_CR10","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","volume":"378","author":"M Jongen-Lavrencic","year":"2018","unstructured":"Jongen-Lavrencic M, Grob T, Hanekamp D et al (2018) Molecular minimal residual disease in acute myeloid leukemia. N Engl J Med 378:1189\u20131199. https:\/\/doi.org\/10.1056\/NEJMoa1716863","journal-title":"N Engl J Med"},{"key":"5733_CR11","doi-asserted-by":"publisher","first-page":"3252","DOI":"10.1200\/JCO.20.01285","volume":"38","author":"E Kastritis","year":"2020","unstructured":"Kastritis E, Leleu X, Arnulf B et al (2020) Bortezomib, melphalan, and dexamethasone for light-chain amyloidosis. J Clin Oncol 38:3252\u20133260. https:\/\/doi.org\/10.1200\/JCO.20.01285","journal-title":"J Clin Oncol"},{"key":"5733_CR12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/13506129.2020.1802713","volume":"28","author":"E Kastritis","year":"2021","unstructured":"Kastritis E, Kostopoulos IV, Theodorakakou F et al (2021a) Next generation flow cytometry for MRD detection in patients with AL amyloidosis. Amyloid 28:19\u201323. https:\/\/doi.org\/10.1080\/13506129.2020.1802713","journal-title":"Amyloid"},{"key":"5733_CR13","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1056\/NEJMoa2028631","volume":"385","author":"E Kastritis","year":"2021","unstructured":"Kastritis E, Palladini G, Minnema MC et al (2021b) Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N Engl J Med 385:46\u201358. https:\/\/doi.org\/10.1056\/NEJMoa2028631","journal-title":"N Engl J Med"},{"key":"5733_CR14","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","volume":"30","author":"S Kumar","year":"2012","unstructured":"Kumar S, Dispenzieri A, Lacy MQ et al (2012) Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 30:989\u2013995. https:\/\/doi.org\/10.1200\/JCO.2011.38.5724","journal-title":"J Clin Oncol"},{"key":"5733_CR15","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s00432-021-03653-z","volume":"148","author":"X Li","year":"2022","unstructured":"Li X, Huang B, Liu J, Chen M, Gu J, Li J (2022) Clinical value of minimal residual disease assessed by multiparameter flow cytometry in amyloid light chain amyloidosis. J Cancer Res Clin Oncol 148:913\u2013919. https:\/\/doi.org\/10.1007\/s00432-021-03653-z","journal-title":"J Cancer Res Clin Oncol"},{"key":"5733_CR16","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41408-020-00377-0","volume":"10","author":"A Medina","year":"2020","unstructured":"Medina A, Puig N, Flores-Montero J et al (2020) Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma. Blood Cancer J 10:108. https:\/\/doi.org\/10.1038\/s41408-020-00377-0","journal-title":"Blood Cancer J"},{"key":"5733_CR17","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-018-0034-3","volume":"4","author":"G Merlini","year":"2018","unstructured":"Merlini G, Dispenzieri A, Sanchorawala V et al (2018) Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Primers 4:38. https:\/\/doi.org\/10.1038\/s41572-018-0034-3","journal-title":"Nat Rev Dis Primers"},{"key":"5733_CR18","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097. https:\/\/doi.org\/10.1371\/journal.pmed.1000097","journal-title":"PLoS Med"},{"key":"5733_CR19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1080\/13506129.2019.1666709","volume":"27","author":"E Muchtar","year":"2020","unstructured":"Muchtar E, Dispenzieri A, Jevremovic D et al (2020) Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis. Amyloid 27:13\u201316. https:\/\/doi.org\/10.1080\/13506129.2019.1666709","journal-title":"Amyloid"},{"key":"5733_CR20","doi-asserted-by":"publisher","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","volume":"4","author":"NC Munshi","year":"2020","unstructured":"Munshi NC, Avet-Loiseau H, Anderson KC et al (2020) A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv 4:5988\u20135999. https:\/\/doi.org\/10.1182\/bloodadvances.2020002827","journal-title":"Blood Adv"},{"key":"5733_CR21","doi-asserted-by":"publisher","first-page":"3613","DOI":"10.1182\/blood-2010-12-324665","volume":"117","author":"B Paiva","year":"2011","unstructured":"Paiva B, V\u00eddriales MB, P\u00e9rez JJ et al (2011) The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis. Blood 117:3613\u20133616. https:\/\/doi.org\/10.1182\/blood-2010-12-324665","journal-title":"Blood"},{"key":"5733_CR22","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","volume":"30","author":"G Palladini","year":"2012","unstructured":"Palladini G, Dispenzieri A, Gertz MA et al (2012) New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 30:4541\u20134549. https:\/\/doi.org\/10.1200\/JCO.2011.37.7614","journal-title":"J Clin Oncol"},{"key":"5733_CR23","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41408-021-00428-0","volume":"11","author":"G Palladini","year":"2021","unstructured":"Palladini G, Paiva B, Wechalekar A et al (2021) Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis. Blood Cancer J 11:34. https:\/\/doi.org\/10.1038\/s41408-021-00428-0","journal-title":"Blood Cancer J"},{"key":"5733_CR24","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","volume":"132","author":"A Perrot","year":"2018","unstructured":"Perrot A, Lauwers-Cances V, Corre J et al (2018) Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood 132:2456\u20132464. https:\/\/doi.org\/10.1182\/blood-2018-06-858613","journal-title":"Blood"},{"key":"5733_CR25","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3390\/ijms23010025","volume":"23","author":"Y Saito","year":"2021","unstructured":"Saito Y, Nakamura K, Ito H (2021) Molecular mechanisms of cardiac amyloidosis. Int J Mol Sci 23:25. https:\/\/doi.org\/10.3390\/ijms23010025","journal-title":"Int J Mol Sci"},{"key":"5733_CR26","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41408-021-00511-6","volume":"11","author":"S Sarosiek","year":"2021","unstructured":"Sarosiek S, Varga C, Jacob A, Fulciniti MT, Munshi N, Sanchorawala V (2021) Detection of minimal residual disease by next generation sequencing in AL amyloidosis. Blood Cancer J 11:117. https:\/\/doi.org\/10.1038\/s41408-021-00511-6","journal-title":"Blood Cancer J"},{"key":"5733_CR27","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/ajh.25746","volume":"95","author":"S Sidana","year":"2020","unstructured":"Sidana S, Muchtar E, Sidiqi MH et al (2020) Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis. Am J Hematol 95:497\u2013502. https:\/\/doi.org\/10.1002\/ajh.25746","journal-title":"Am J Hematol"},{"key":"5733_CR28","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1182\/bloodadvances.2019001331","volume":"4","author":"A Staron","year":"2020","unstructured":"Staron A, Burks EJ, Lee JC, Sarosiek S, Sloan JM, Sanchorawala V (2020) Assessment of minimal residual disease using multiparametric flow cytometry in patients with AL amyloidosis. Blood Adv 4:880\u2013884. https:\/\/doi.org\/10.1182\/bloodadvances.2019001331","journal-title":"Blood Adv"},{"key":"5733_CR29","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41408-021-00529-w","volume":"11","author":"A Staron","year":"2021","unstructured":"Staron A, Zheng L, Doros G et al (2021) Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study. Blood Cancer J 11:139. https:\/\/doi.org\/10.1038\/s41408-021-00529-w","journal-title":"Blood Cancer J"},{"key":"5733_CR30","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/s41375-020-1006-7","volume":"35","author":"R Szalat","year":"2021","unstructured":"Szalat R, Sarosiek S, Havasi A, Brauneis D, Sloan JM, Sanchorawala V (2021) Organ responses after highdose melphalan and stemcell transplantation in AL amyloidosis. Leukemia 35:916\u2013919. https:\/\/doi.org\/10.1038\/s41375-020-1006-7","journal-title":"Leukemia"},{"key":"5733_CR31","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","volume":"8","author":"JF Tierney","year":"2007","unstructured":"Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8:16. https:\/\/doi.org\/10.1186\/1745-6215-8-16","journal-title":"Trials"},{"key":"5733_CR32","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/jebm.12141","volume":"8","author":"X Zeng","year":"2015","unstructured":"Zeng X, Zhang Y, Kwong JS et al (2015) The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review. J Evid Based Med 8:2\u201310. https:\/\/doi.org\/10.1111\/jebm.12141","journal-title":"J Evid Based Med"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-05733-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-024-05733-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-05733-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T04:08:29Z","timestamp":1716437309000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-024-05733-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,15]]},"references-count":32,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["5733"],"URL":"https:\/\/doi.org\/10.1007\/s00432-024-05733-2","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,15]]},"assertion":[{"value":"6 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"193"}}